Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 12.18B 10.65B 9.78B 9.12B 17.29B 1,159B 17.55B 117B 45.66B 570B 45.7B 44.72B 1,965B P/E 2026 *
-75.7x
P/E 2027 * 53.5x
Enterprise Value 11.65B 10.18B 9.36B 8.72B 16.54B 1,109B 16.79B 112B 43.67B 545B 43.71B 42.77B 1,880B EV / Sales 2026 *
7.79x
EV / Sales 2027 * 5.02x
Free-Float
94.32%
Yield 2026 *
-
Yield 2027 * -
1 day+2.67%
1 week+3.01%
Current month-1.65%
1 month+7.16%
3 months-3.44%
6 months-11.07%
Current year-9.31%
1 week 506
Extreme 506
545.87
1 month 460.89
Extreme 460.89
545.87
Current year 416.21
Extreme 416.21
598.79
1 year 284.02
Extreme 284.0228
615
3 years 119.76
Extreme 119.7604
615
5 years 52.33
Extreme 52.33
615
10 years 6.6
Extreme 6.6
615
Manager TitleAgeSince
Chief Executive Officer 59 2023-09-07
Director of Finance/CFO 62 2024-03-10
Chief Tech/Sci/R&D Officer 58 2025-04-20
Director TitleAgeSince
Chairman 83 2016-07-21
Director/Board Member 73 2016-06-30
Director/Board Member 68 2016-08-10
Date Insider Type Main position Quantity % Market Cap.
06-16Free

Director

1,220 0.0053%
06-16Free

Director

1,220 0.0053%
06-16
Baker Bros. Advisors LP
FreeCompany 4,880 0.0212%
Change 5-day change 1-year change 3-year change Capi.($)
+2.67%+3.01%+76.70%+133.90% 12.18B
+0.68%+5.92%+77.86%+139.22% 59.1B
+2.32%+5.03%+75.26%+91.40% 55.19B
+3.86%+6.93%-11.32%-9.53% 24.67B
+4.30%+7.95%+14.11%+437.83% 24.19B
+4.74%+13.68%+43.36%-4.67% 19.69B
-0.29%+9.78%+43.90%-28.41% 17.56B
0.00%+20.78%+186.15%+361.42% 16.22B
+6.72%+19.38%+37.85% - 14.84B
+3.50%+1.97%+21.02%+191.95% 14.04B
Average +2.85%+7.99%+56.49%+145.90% 25.77B
Weighted average by Cap. +2.47%+6.30%+59.19%+136.82%

Financials

2026 *2027 *
Net sales 1.5B 1.31B 1.2B 1.12B 2.12B 142B 2.16B 14.35B 5.61B 69.96B 5.61B 5.49B 241B 2.21B 1.93B 1.77B 1.65B 3.13B 210B 3.18B 21.16B 8.27B 103B 8.28B 8.1B 356B
Net income -201M -176M -162M -151M -285M -19.14B -290M -1.93B -754M -9.4B -754M -738M -32.44B 308M 269M 247M 230M 437M 29.29B 444M 2.95B 1.15B 14.39B 1.15B 1.13B 49.66B
Net Debt -529M -463M -425M -396M -751M -50.38B -763M -5.08B -1.98B -24.76B -1.99B -1.94B -85.42B -1.09B -957M -880M -820M -1.55B -104B -1.58B -10.5B -4.1B -51.21B -4.11B -4.02B -177B
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
26-07-02 US$528.10 +2.67% 221,894
26-07-01 US$514.39 -4.20% 303,751
26-06-30 US$536.95 +1.83% 393,459
26-06-29 US$527.28 +2.85% 446,960
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
528.10USD
Average target price
678.71USD
Spread / Average Target
+28.52%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MDGL Stock